Immunotherapy plus chemoradiation for inoperable stage III lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of immunotherapy and chemotherapy before and after standard chemoradiation for patients with stage III lung cancer that cannot be surgically removed. The goal is to see if this approach improves outcomes compared to chemoradiation alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have a type of lung cancer called non-small cell lung cancer that cannot be surgically removed
- Your cancer is stage III (spread to nearby lymph nodes but not distant organs)
- You have not had any prior cancer treatment for this disease
- You have good organ function (heart, lungs, liver, kidneys) and are generally healthy enough for treatment
- You are willing and able to give informed consent and follow the study plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining chemotherapy with immunotherapy before and after chemoradiation helps people with stage III lung cancer that can be removed by surgery. It might improve how well treatment works and reduce the chance of cancer coming back.
This trial tests giving chemotherapy, immunotherapy, and targeted radiation before surgery for people with non-small cell lung cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
This trial tests a new approach for people with stage III lung cancer that cannot be removed with surgery. You would receive immunotherapy (to help your immune system fight cancer) plus chemotherapy first, then standard chemo-radiation, and finally more immunotherapy. The goal is to see if this sequence works better than standard treatment.
This trial tests a new schedule of chemo-radiation (fewer, stronger sessions) followed by an immunotherapy drug called tislelizumab. The goal is to see if this approach works better than the standard longer schedule for people with stage III lung cancer that can't be surgically removed.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial combines surgery to remove the main lung tumor with chemo and an immunotherapy drug called sintilimab. It's for people with advanced non-small cell lung cancer that hasn't been treated before and doesn't have certain gene changes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.